Abstract 547P
Background
Immunotherapy is now standard of care in advanced/metastatic lung cancer patients either in first line alone or in combination with chemotherapy, also in subsequent lines. Here, we presenting real world outcome with immunotherapy in lung cancer patients from India.
Methods
We performed an analysis of prospectively collected data of patients with advanced/metastatic lung cancer treated at a single academic cancer centre in India. The patient’s demographic data, treatment details, toxicity and response to treatment captured from electronic medical record of each patient. Data was analysed for safety and survival outcome.
Results
From August 2015 to September 2021, 164 eligible patients were included in this study. Median age at presentation was 59 year (range 21 year to 86 year). 82% (n=134) were male and 18% (n=34) were female (M: F 4.5:1). At presentation, 73% (n=118) were ECOG PS 0 or 1, 14.5% (n=24) were ECOG PS 2, and 12.5% (n=22) were ECOG PS 3 or 4. Out of 164, 33% (n = 54), received immunotherapy drug in first line, 46% (n = 76) in second line, 21% (n = 34) in third line and beyond. 65% (n=106) received Nivolumab, 26.5% (n=44) received Pembrolizumab, 8.5% (n=14) received Atezolizumab. Median progression free survival and median overall survival was 5 months (95% CI 3.5 to 6.5 month) and 10 months (95% CI 7.3 to 12.7 month) respectively. Overall, 3-year PFS and OS rate is 5% and 23%. Fatigue was most common seen in 15% patients, hyponatremia in 5.3%, anorexia in 2.4%. Among immune-related toxicity- pneumonitis was most common seen in 4.8%, followed by hypothyroidism in 3.8%, transaminitis and nephritis in 1.9% each, skin rash, colitis, and encephalitis in 1.4% each, adrenal insufficiency and hypophysitis in 1% each seen.
Conclusions
In real world, immunotherapy having clinically significant benefit on survival in advanced/metastatic lung cancer patients with acceptable safety profile including patients with borderline performance status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract